Protective effect of Sheng-Mai Yin, a traditional Chinese preparation, against doxorubicin-induced cardiac toxicity in rats by Shaojun Ma et al.
RESEARCH ARTICLE Open Access
Protective effect of Sheng-Mai Yin, a
traditional Chinese preparation, against
doxorubicin-induced cardiac toxicity in rats
Shaojun Ma1†, Xiaojiang Li2†, Liang Dong2†, Jinli Zhu2, He Zhang1 and Yingjie Jia2*
Abstract
Background: Sheng-Mai Yin (SMY), a modern Chinese formula based on Traditional Chinese Medicine theory, has
been used to treat cardiovascular diseases in Eastern Asia. Our study focuses on the cardioprotection of SMY
against doxorubicin (DOX)-induced cardiac toxicity in vivo.
Methods: Rats were injected with DOX (2.5 mg/kg) in six injections over a 2-week period. SMY was administrated
intragastrically at the dose of 8.35, 16.7 and 33.4 g/kg, or 16.7 g/kg only twice a day concurrently with DOX for the
2-weeks. A series of assays were performed to detect the effects of SMY on: (i) heart weight index (HWI) and left
ventricular mass index (LVMI); (ii) cardiac function; (iii) heart tissue morphology; (iv) the contents of carboxy terminal
propeptide of procollagen typeI (PICP), amino terminal propeptide of procollagen type III (PШNP), transforming
growth factor-β1 (TGF-β1), B-type natriuretic peptide (BNP), monocyte chemoattractant protein-1 (MCP-1), interferon
gamma (INF-γ) and interleukin 6 (IL-6) by ELISA; (v) the mRNA levels of TGF-β1 and toll-like receptor-2 (TLR2); and
(vi) protein level of TGF-β1.
Results: Rats treated with SMY displayed the reductions of BNP and CK-MB increased by DOX in a dose-dependent
manner. Moderate dose of SMY exhibited the correction for the increased HWI, LVMI, and the injured cardiac
function, as well as the collagen accumulation. In addition, cardioprotection of SMY against DOX-induced
cardiac toxicity was demonstrated by the reduction of myocardial fibrosis, characterized by the suppression of
PICP, PШNP and TGF-β1, as well as the anti-inflammation and the regulation for cardiac immune
microenvironment, characterized by the inhibition of TLR2, MCP-1, INF-γ and IL-6.
Conclusions: SMY may protect heart function through the restriction of myocardial fibrosis induced by DOX,
which suggests the potentially therapeutic effect of SMY on DOX-induced cardiomyopathy.
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Background
Doxorubicin (DOX), a broad spectrum anthracycline an-
tineoplastic, is widely used for the treatment of various
malignancies such as acute leukemia, lymphoma and
breast cancer [1, 2]. Unfortunately, clinical applicationsof
this drug are restricted due to the severe, dose-dependent,
acute cardiotoxicity that may involve various signaling
pathways including free radical generation, peroxynitrite
formation, calcium overloading, mitochondrial dysfunc-
tion, alteration in beta-adrenergic receptor signaling, and
activation of matrix metalloproteinase [3, 4] which will in-
evitably lead to congestive heart failure [2, 5]. Moreover,
some studies have found that patients receiving DOX
therapy had an increased risk of myocardial infarction
(MI) and this risk persisted up to 25 years after DOX
treatment [6]. Over the past decade, adjuvant therapies
have been proposed to decrease the cardiotoxic effects of
DOX. For instance, the use of antioxidants such as probu-
col, taurine and fenofibrate has been shown to suppress
DOX-induced oxidative stress and cardiac myocyte apop-
tosis [7–9]. Despite various therapeutic interventions
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adopted to protect the heart against DOX-induced cardio-
toxicity, the deterioration in cardiac functions is often ac-
companied by high mortality rates [10]. Hence, further
therapeutic agent development especially the pharmaco-
dynamic constituents from natural herb in complemen-
tary and alternative medicine (CAM) have been regarded
as the focus in the amelioration of DOX-induced cardiac
damage.
Traditional Chinese medicine (TCM) has a 3000-year-
old history that includes unique theories for aetiology
and systems of diagnosis and treatment. Nowadays, it is
widely accepted that multiple ingredients counteract
chemotherapy-induced gastrointestinal toxicity and
kansui-induced hepatocyte cytotoxicity [11, 12]. Sheng-
Mai Yin (SMY), a traditional Chinese formula widely
used for coronary heart disease treatment with “qi–yin”
deficiency, consists of three herbal materials of Radix gin-
seng (invigorates Qi and dispels stagnation), Radix ophio-
pogonis (nourishes Yin and grows succus) and Fructus
schisandrae (invigorates Qi) [13]. A series of animal stud-
ies have reported that Shengmai preparation could im-
prove the glutathione peroxidase (GSH-Px) activities,
superoxide dismutase (SOD) activity [14], Ca2+-ATP en-
zyme activity and myocardial ultrastructure [15] of DOX-
injured rats myocardial tissue. In addition, anti-apoptosis
effect of Shengmai injection was also observed in DOX-
induced rats, characterized by the reduction of Bax pro-
tein and the increase of Bcl-2 protein [16]. Consequently,
it seemed that Shengmai treatment had an effect in DOX-
induced cardiac toxicity model. Although there is a lot of
research regarding SMY’s cardioprotecion, few of them in-
volved in the myocardial fibrosis induced by DOX. There-
fore, this study investigated protective effects of SMY on
DOX-induced myocardial fibrosis. The rat models in-
duced by DOX were employed and many pharmacological
indicators including electrocardiogram, cardiac func-
tion and myocardial fibrosis analysis were observed.
Methods
Animals
The study protocol was approved by the Institutional
Animal Care and Use Committee of Tianjin University
of Traditional Chinese Medicine and in accordance with
the principles outlined in the NIH Guide for the Care
and Use of Laboratory Animals. Thirty adult Sprague–
Dawley male rats (SPF grade) weighing 235 ± 20 g, 7- to
8-week-old, were kept in standard cages at 25 ± 1 °C
under a 12-h light/dark cycle and fed a rodent standard
diet with free access to water. According to the mean
and standard deviation of PICP in preliminary experi-
ment, we calculated the sample size as 24 rats with soft-
ware SAS9.2 (α = 0.05,β = 0.1, power = 0.9). Considering
the possible animal deaths in the 2-weeks, we involved
totally 30 rats in the experiment. The rats were
numbered and randomized into three groups according
to the random number generated by rand function of
EXCEL: control group (n = 10), DOX group (n = 10), and
DOX + SMY group (n = 10). 10 rats in DOX group were
administered DOX and 10 rats in DOX + SMY group
were administered DOX + SMY.
Sheng-Mai Yin (SMY) preparation
The SMY was composed by Radix ginseng, Radix ophiopo-
gonis and Fructus schisandrae at the ration of 1:2:1. To
keep the consistency of the herbal chemical ingredients, all
of the herbal components were originally obtained from
the standard native sources as stated above with GAP
grade. All of these herbal materials (Heyanling Chinese
Herbal Medicine Co., Ltd., Beijing, China) were the same
batch during the whole experimental processand were
identified by School of Pharmacy, Tianjin University of
Traditional Chinese Medicine. A voucher specimen of
each species was also deposited at Tianjin University of
Traditional Chinese Medicine. To prepare the SMY [17],
the mixture of the three herbs were pulverized to coarse
powder, macerated in 65 % (vol/vol, in H2O) ethanol
(11.5 mL/g) for 24 h, and then extracted by percolation.
The extracts were concentrated, followed by removing un-
dissolved particulates by filtration. The mixture was ad-
justed to pH 6. The liquid of SMY was sterilized by
0.22 μm filter before the administration. Using these pro-
cedures, the total concentration of the SMY was 0.375 g/
mL (crude drug content) based on data from processing
and stability studies. The SMY was stored at 4 °C for use.
Drugs and animal treatment
Rats were treated with DOX (Sigma, St. Louis, MO, USA)
as previously reported with modification. In brief, rats were
injected i.p. with DOX (2.5 mg/kg) dissolved in normal sa-
line every other day (Monday, Wednesday, and Friday)
over a 2 week period (total six injections) to produce a total
cumulative dose of 15 mg/kg body weight [18]. In clinical,
the adult dose of Shengmai Yin was 2.0875 g/kg and the
equivalent in rats was 16.7 g/kg which was used as moder-
ate dose. In treatment group, rats were given SMY concur-
rently with DOX at the dose of 8.35, 16.7 and 33.4 g/kg as
the low, moderate and high doses respectively (moderate
dose was converted according to the clinical adult dosage)
twice a day during the 2-week period via intragastric ad-
ministration. Therats in high-dosage and low-dosage group
received SMY at a dose 2 fold moderate and half a moder-
ate, respectively (33.4 g/kg, 8.35 g/kg). Control animals re-
ceived the vehicle (saline) only.
Body weight, heart weight index (HWI) and left
ventricular mass index (LVMI) calculation
The body weight of rat was recorded everyday. All the rats
had echocardiographic assessment and were sacrificed the
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day after the last SYM administration. Heart tissues were
excised, rinsed with cold PBS solution, and the left ven-
tricle was separated from the atria, aorta and adipose tis-
sue. The left ventricle weight (LVW, mg) and heart weight
(HW, mg) were weighed, and then left ventricular weight
index (LVMI, mg/g) and heart weight index (HWI, mg/g)
were calculated by the ratios of the LVW to the body
weight and the HW to the body weight, respectively.
Electrocardiography and the echocardiography
The ECG was monitored at the end of experiment by
Biopac MP150 data acquisition system. Cardiac function
was determined by transthoracic echocardiography as
previously described [19]. The rats were anesthetized
with 1 % sodium pentobarbital and were fixed on the
board. The hairs of rats were removed in the ventral
chest area and front area. There is the echocardiography
probe which emits and receives ultrasound in the range
of 5–12 MHz. The LVEDD and LVESD were measured.
The EF was calculated using the formula as follows: EF
= [(LVEDD3 − LVEDS3)/LVEDD3] × 100 % [20]. For each
rat, two measurements were performed: 1 day before the
onset of experiment and the end of experiment.
Morphological examination
The histopathological evaluations including hematoxylin-
eosin staining (H&E) and Masson staining in each group
were conducted by standard histological techniques. The
heart tissues were fixed in 10 % buffered formalin and em-
bedded in paraffin. The 5 μm sections were stained with
H&E. As for the Masson staining, sections were incubated
in Bouins Fixative for 45 min, washed and stained with
weigert iron hematoxylin, anylin blue, and finally mounted
with cytoseal-60 and cover slip. Each slide was analyzed
under a brightfield microscope with the fibrotic areas
stained in blue and the healthy in red. All photos were an-
alyzed with the image-proplus 6.3 analyzing software
(Media Cybernetics, Bethesda, MD, USA) by computer.
Enzyme-linked immunosorbent assay (ELISA)
Serum or plasma was prepared from peripheral blood.
Heart tissues were removed, homogenated with ice-cold
PBS, centrifuged at 12,000 rpms for 20 min and separated
the supernatant. The levels of procollagen type 1 (PICP),
amino terminal propeptide of procollagen type III (PIIINP)
and B-type natriuretic peptide (BNP) levels in serum, as
well as transforming growth factor-β1 (TGF-β1), monocyte
chemoattractant protein-1 (MCP-1), interferon gamma
(INF-γ) and interleukin 6 (IL-6) in the heart tissue were
measured by ELISA according to the manufacture instruc-
tions and calculated according to the standard curve. Cre-
atine kinase MB isoenzyme (CK-MB) level in the plasma
was determined by spectrophotometry.
mRNAs detection
TGF-β1 mRNA expression in the heart tissue was ob-
served by Reverse transcription (RT) polymerase chain
reaction (PCR) as described [21]. In short, total RNA
from heart tissue was extracted using TRIZOL reagent
(Invitrogen). Two μL of total RNA were used for reverse
transcription to obtain cDNA by a cDNA synthesis kit
(Fermentas). Each cDNA was used successively to amp-
lify TGF-β1 and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) (loaded as a control). Amplification
was performed with a reaction protocol of Ampli-
TaqDNA polymerase (Fermentas) at 94 °C for 3 min
followed by 30 cycles at 94 °C (40 s), 60 °C (30 s), and
72 °C (45 s) and 72 °C (10 min). The bands of PCR
products separated by agarose gel electrophoresis (Bio-
West) were analyzed via the IS-1000 analyzer system.-
cDNA was also subjected to real-time quantitative PCR
with toll-like receptor-2 (TLR2) primers and Power SYBR
Green PCR Master Mix (Applied Biosystems, Foster City,
CA, USA) using the ABI 7000 sequence detection system
(Applied Biosystems). The data of TLR2 was analyzed
using the ABI 7000 system SDS software and deter-
mined by the 2−ΔΔCt method. The sequences of primers
were shown as follows: TGF-β1 (5′- GGCGGTGCTCG
CTTTGT-3′/5′- GCCCTGTATTCCGTCTCCTT −3′),
fragment length was 424 bp. TLR2 (5′- ATGCTGCAAGC
TCTTTGGCTCTTC-3′/5′- AGTCACCAfGGCCAATGT
AGGTG −3′), fragment length was 241 bp. β-actin (5′- T
GTGCTATGTTGCCCTAGACT −3′/5′- ACGTACTC
CTGGTTGCTGAT −3′), fragment length was 493
bp. GAPDH (5′- AGAAGGCTGGGGCTCATTTG-3′/
5′- AGGGGCCATCCACAGTCTTC-3′), fragment length
was 257 bp.
Western blots
TGF-β1 expression in the heart tissue was conducted by
western blots according to standard protocols.
Briefly, heart tissues were rinsed with ice-cold PBS
and scraped in lysis buffer. The insoluble material
was removed by centrifugation at 12,000 rpms for
20 min. Fifty micrograms protein was processed by
SDS-PAGE separation in 12 % gel, followed by the
transfer to a 0.45 μm nitrocellulose membrane. Tris–
HCl buffered saline (TBS) containing 5 % nonfat dry
milk was used to block the non-specific binding
sites. The membrane was then incubated with pri-
mary antibodies (1:2000 dilution) against TGF-β1, or
against β-actin (1:5000 dilution) as controls, followed
by incubation with the corresponding horseradish
peroxidase (HRP)-conjugated secondary antibodies
(1:10,000 dilution). Immunoreactive proteins were de-
tected by enhanced chemiluminescence according to
the instructions of the manufacturer (Pierce, Rock-
ford, IL).
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Statistical analysis
The experimental data were represented as mean ±
standard deviation (SD). One way analysis of variance
(ANOVA) was used to determine statistically significant
differences among the groups. A P-value of <0.05 was
considered to be statistically significant.
Results
Effects of SMY with different doses on BNP and CK-MB
The gray scale image in Fig. 1 displayed the obvious
increases of BNP and CK-MB in DOX group which
suggests cardiac injury. However, treatment with
SMY with low, moderate and high dose significantly
inhibited the level of BNP in a dos -dependent man-
ner (Fig. 1a, P < 0.05 or P < 0.01), with the reduction
of 16.29 %, 23.28 % and 33.97 % respectively. Mean-
while, SMY also suppressed CK-MB content in a
dose dependent manner (Fig. 1b, P < 0.05 or P < 0.01).
Based on the above results, we chose the moderate
dose of 16.7 g/kg in the following experiments.
Effects of SMY on cardiac weight indexes
The effects of SMY on HWI (HW/body weight) and
LVMI (LVW/ body weight) were shown in Fig. 2. Before
the treatment, the baseline of LVMI was the same be-
tween different groups (Fig. 2c). The HWI (Fig. 2b) and
LVMI (Fig. 2d) were significantly greater in the DOX
treated group than those in the control group due to the
decrease of body weight. After the treatment for 2 weeks
by SMY, HWI and LVMI were respectively recovered to
3.49 ± 0.145 mg/g and 2.67 ± 0.21 mg/g, with a statistical
significance (P <0.05).
Effects of SMY on physiological indexes
The results of our physiological studies were summarized
in Fig. 3. The baselines of cardiac function in each group
have no significant difference (Fig. 3b-d) before DOX or
SMY treatment was administered. Rats receiving DOX
alone had significant cardiac functional deterioration, char-
acterized by increased heart rate, ST segment depression,
elevated T wave (Fig. 3a); and signs of decreased cardiac
function, i.e. increased LVEDD and LVESD, decreased EF
as compared with control animals. Treatment with SMY
significantly mitigated the DOX induced impairment of
cardiac function, characterized by the reversal of LVEDD
(Fig. 3e), LVESD (Fig. 3f) and EF (Fig. 3g).
Effects of SMY on morphological changes and fibrosis
related proteins
Hhistopathological study (Fig. 4a) showed that rats in
the control group had normal tissue morphology. As
shown in DOX group rats, many myocardial structure
disorders of muscle fibers and the infiltration of acute
inflammatory cells were observed. The architecture in
the rats treated by SMY was recovered to some extent.
In addition, little amount of collagen was found in the
interstitial and perivascular space in normal control rats
(Fig. 4b). Under microscope, there was a large accumula-
tion of collagen in the ventricle of DOX-injured rats,
stained by blue. Less collagen deposition was found in
SMY groups than that in DOX group. The bar graph in
Fig. 4c showed a significant decrease in interstitial fibro-
sis (mm2) in the rats who received SMY treatment. In
order to clarify the material basis of morphological
changes further, we continued to explore the proteins
correlated with myocardial fibrosis, such as PICP and
PIIINP. DOX significantly increased the secretion of
PICP (Fig. 4d: 1.98-fold, P < 0.001) and PШNP (Fig. 4e:
1.9-fold, P < 0.001). Treatment for 2 weeks by SMY re-
sulted in suppression of PICP and PIIINP contents; with
a reduction of 28.75 % and 29.05 % respectively.
Effects of SMY on TGF-β1
As shown in Fig. 5a, DOX significantly increased the
level TGF-β1 in the serum detected by ELISA (1.73-fold,
Fig. 1 a Bar graphs showed the changes of BNP content
determined via ELISA assay. SMY of both moderate dose and high
dose suppressed the BNP content, with a significant reduction as
compared to group DOX. b Bar graphs show the changes of CK-MB in
serum. The CK-MB level was significantly inhibited by the SMY in a
dose-dependent manner. Eight to ten rats in each group were
analyzed in this experiment and all data were represented as
mean ± standard deviation. ** P < 0.01 versus the group control, *** P
< 0.001 versus the group control; #P < 0.05 versus the group DOX; ##P
< 0.01 versus the group DOX
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Fig. 2 Effects of SMY on body weight (a), heart weight index (b) and left ventricular mass index (d) in rats with DOX-induced cardiomyopathy.
c Baseline of left ventricular mass index before treatment. Ten rats in each group were analyzed in this experiment and all data were represented
as mean ± standard deviation. ** P < 0.01 versus the group control; #P < 0.05 versus the group DOX; ##P < 0.01 versus the group DOX
Fig. 3 Electrocardiogram changes (a) in different groups. Baseline of left ventricular end diastolic dimension (b), left ventricular end systolic dimension
(c) and ejection fraction (d) before the onset of the experiments. Effects of SMY on left ventricular end diastolic dimension (e), left ventricular end systolic
dimension (f) and ejection fraction (g) in rats with DOX-induced cardiomyopathy. Ten rats in each group were analyzed in this experiment and all data
were represented as mean ± standard deviation. ** P< 0.01 versus the group control; #P< 0.05 versus the group DOX
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P < 0.001) which was significantly inhibited by SMY, with
a reduction of 23.87 % (P < 0.001). The levels of TGF-β1
in both mRNA (Fig. 5c) and protein (Fig. 5b) were up-
regulated in the DOX group by 3.4-fold (P < 0.05) and
2.34-fold (P < 0.05) respectively as compared with the
control in response to DOX. Compared with the DOX
group, SMY significantly down-regulate both mRNA
level and protein level of TGF-β1 by 64.36 % and 37.1 %,
respectively (P < 0.05). Data from immunostaining and
quantification of TGF-β1 were also shown in Fig. 5d.
Fig. 4 Representative photomicrographs of H&E staining on myocardial morphology (a) and interstitial fibrosis (b), with fibrotic tissue in blue and
healthy cardiac tissue in pink and vascular fibrosis. Bar graph (c) showed a significant decrease in interstitial fibrosis (mm2) by SMY. Three rats in
each group were analyzed in this experiment. (d) Effects of SMY on PICP, and PШNP (e) in rats with DOX-induced cardiomyopathy detected by
ELISA. Six rats in each group were analyzed in ELISA assay and all data were represented as mean ± standard deviation. ** P < 0.01 versus the
group control, *** P < 0.001 versus the group control; #P < 0.05 versus the group DOX, ###P < 0.001 versus the group DOX
Fig. 5 a Effects of SMY on TGF-β1 levels in rats with DOX-induced cardiomyopathy detected by ELISA which included six rats in each group.
b Immunoblots of left ventricle were probed with anti- TGF-β1, while anti-β-actin antibody served as the loading controls. c Changes in TGF-β1
mRNA expression in left ventricle. d Bar graphs showed the relative density of TGF-β1 bands in left ventricle. Three rats were analyzed in PCR and
western blots experiments. All data were represented as mean ± standard deviation. *** P < 0.001 versus the group control; ###P < 0.001 versus
the group DOX
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The change of mRNA was consistent with that of pro-
tein which indicated that the regulation of SMY for the
TGF-β1 was mediated by transcription mechanism.
Effects of SMY on inflammatory factors
Bar graphs in Fig. 6 displayed that DOX administration
induced a high expression of TLR2 mRNA (Fig. 6a) and
the amounts of inflammatory factors of MCP-1 (Fig. 6b),
INF-γ (Fig. 6c) and IL-6 (Fig. 6d) as compared with the
control group (P < 0.05, P < 0.01 or P < 0.001). When ex-
posed under SMY, the TLR2 mRNA level was down-
regulated by 47.11 %. The contents of MCP-1, INF-γ
and IL-6 in SMY-treated heart tissue were also sup-
pressed significantly as compared with DOX group, with
reduction of 70.48 %, 50.35 % and 50.17 %, respectively
(P < 0.05 or P < 0.001).
Discussion
In spite of being an effective anti-cancer agent, DOX
usage at maximal therapeutic dose is life threatening due
to its accumulation in the circulation which may induce
irreversible cardiomyopathy and heart failure [22]. Fol-
lowing DOX treatments, aberrations to myocardial
architecture and function include cardiac cell hyper-
trophy and death, heightened susceptibility to myocar-
dial infarction (MI), cardiomyopathy, and left ventricular
dysfunction [23–25]. Many CAMs show significant im-
provements in chemotherapy- or radiotherapy-related
side effects and TCM is the most common means of
CAM in China. Shengmai, as a traditional Chinese
medicine, is usually used in China as a complementary
treatment to western treatments that are recommended
for acute heart failure, and also as a single treatment for
chronic heart failure [26]. Previous studies have focused
on the study of SMY on ischemic cardiomyopathy [27, 28]
or contractile function of aged hearts [17]. There are few
reported studies about SMY on non-ischemic cardiomy-
opathy, such as DOX-induced cardiomyopathy and heart
failure. Our study provides the important evidence of the
beneficial effects of SMY on cardiac dysfunction resulting
from DOX-induced heart injury in terms of myocardial fi-
brosis. We showed a dose-dependent cardioprotecion of
SMY in a rat model induced by DOX, characterized by
the suppression of BNP and CK-MB, the biomarkers for
myocardial infarction and the biochemical criteria of myo-
cardial infarction diagnosis. In agreement with the out-
comes of previous studies, DOX induced signs of
cardiomyopathy in the form of decreased BW, increased
heart index and left ventricular mass index, indicating a
severe dysfunction in cardiac performance [29, 30]. We
found that administration of clinical equivalent dose of
SMY during the injury of DOX significantly increased
body weight, decreased the HWI and LVMI which sug-
gested that this formula was an effective and safe strategy
for cardiotoxicity.
Echocardiography is a versatile noninvasive tool for
measuring cardiac function and structure in animal as
well as in clinic [31, 32]. The change of T-wave in the
ECG is an important signal that reflects the extent of
heart injury [33, 34]. In our study, the T-wave of the rats
Fig. 6 a. TLR2 mRNA level in DOX-injured cardiac tissue was reversed by SMY remarkably. Three rats were analyzed in PCR experiment. Meanwhile, the
contents of MCP-1 (b), INF-γ (c) and IL-6 (d) were also inhibited significantly by SMY as compared with group DOX. Six rats were analyzed in ELISA assay
and all data were represented as mean ± standard deviation. * P< 0.05 versus the group control, ** P< 0.01 versus the group control, *** P< 0.001 versus
the group control; #P< 0.05 versus the group DOX, ###P< 0.001 versus the group DOX
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was elevated after DOX administration. We used echo-
cardiography to estimate LV function as reflected by
LVEDD, LVESD and EF. The echocardiography records
showed that the baseline of LV function before treat-
ment was consistent, with no statistically significant dif-
ference. SMY significantly attenuated the change of T-
wave amplitude. In addition, SMY also decreased the
LVEDD and LVESD, as well as increased EF, suggesting
that SMY can prevent DOX-induced heart function
deterioration.
Fibrosis plays a major role in adverse cardiac remodeling
in DOX-induced cardiomyopathy (DIC) and post-MI myo-
cardium [35]. The ultra-structural changes seen in endo-
myocardial biopsies of patients with DOX-associated heart
failure include loss of myofibrils, disarray of sarcomere
structure, dilation of the sarcoplasmic reticulum, swelling
of the mitochondria and cytoplasmic vacuolization [36].
As expected, the degree of cardiac injury was displayed by
myocardial structure disorders of muscle fibers as well as
infiltration of acute inflammatory cells, elevated quantities
of interstitial and vascular fibrosis, demonstrable micro-
scopically with an up to approximately 15.8-fold increase
in interstitial fibrosis. Our data further suggested that fol-
lowing SMY administration, accumulation of collagen was
attenuated. This may be one of the main reasons of the
improvement of LVEDD, LVESD and EF.
Serum levels of PICP and PIIINP are the markers of
myocardial fibrosis. Type I collagen is a major compo-
nent of myocardial extracellular matrix and plays a key
role in ventricular remodeling [37]. The other type of
collagen associated with ventricular remodeling is colla-
gen type III (PIIINP), a serum biomarker of myocardial
biosynthesis of type III collagen is associated with poor
left ventricular function and high mortality following
myocardial infarction [38]. Fibrosis plays a major role in
adverse cardiac remodeling in DIC and post myocardial
infarction [35]. In our paper, we showed that the
markers of myocardial fibrosis (PICP and PIIINP) were
increased after the DOX. The serum PICP was de-
pressed in rats administrated with SMY, suggesting the
collagen turnover may have dropped to a lower level. Al-
though the value of serum PIIINP in predicting the DIC
is uncertain, the level of PIIINP is still used as indicators
of myocardial fibrosis in vivo to clarify the influence on
myocardial fibrosis [39]. The administration of SMY for
2 weeks during DOX injury significantly decreased the
content of PIIINP in serum which indicated that SMY
attenuated myocardial fibrosis to some extent.
TGF-β1 is a protein secreted by cardiac myofibroblast
and fibroblast that controls proliferation and is respon-
sible for cardiac apoptosis, hypertrophy, and fibrosis
[40]. Previous report showed that TGF-β1 gene expres-
sion is increased in the left ventricular myocardium of
patients with idiopathic hypertrophic cardiomyopathy or
dilated cardiomyopathy and in animals after myocardial
infarction [41]. In the present study, treating rats with
DOX not only expressed high content of TGF-β1 in
serum, but also exhibited high expression in myocar-
dium. These findings suggest the possible involvement
of TGF-β1 gene and protein in the regulation of DOX-
cardiotoxicity process. We further explored the mRNA
and protein levels of TGF-β1 treated by SMY and found
that the down-regulation of TGF-β1 mRNA by SMY
was consistent with the protein levels which indicated
that the regulation of SMY for TGF-β1 was mediated
through transcriptional mechanism. Combined with the
other results in this paper, we can speculate that the im-
provement of cardiac function and morphology by SMY
maybe mediated by the suppression of fibrosis associated
proteins and gene.
The occurrence and development of chronic inflam-
mation in chronic heart failure is considered to be the
initiating factor in heart tissue fibrosis [42]. The inflam-
matory response caused by injury initiated the processes
of tissue repair which could cause tissue fibrosis. Block-
ade of TLR2 attenuated LV dysfunction and fibrosis in
DOX triggered acute and chronic cardiomyopathy,
which was strongly associated with the reduced inflam-
mation and TLR2 endogenous agonist levels [43]. Stimu-
lation of TLR2 induces a mixed Th1, Th2, Treg, and
Th17 types of immune response, which mainly mediates
the chronic inflammatory and tissue injury responses
[44]. To clarify the inflammation mechanism, we de-
tected TLR2 mRNA and concerned inflammatory fac-
tors. Treatment of DOX-injured rats with SMY reduced
TLR2 mRNA expression and the levels of MCP-1, IL-6
(a typical Th2-type cytokine) and INF-γ (a typical Th1-
type cytokine). Combined with TGF-β (a Treg cytokine),
our analysis for the Th1/Th2/Treg suggested that anti-
inflammation and the regulation for cardiac immune
microenvironment might be other possible mechanisms
for the reversal of myocardial fibrosis by SMY.
Conclusions
SMY exhibited cardioprotection on DOX in rats, which
might be attributable to the improvement of heart func-
tion, the attenuation of myocardial fibrosis and the
down-regulation of fibrosis associated protein. Further
studies are required to identify the mechanisms behind
the SMY.
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